X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SANOFI INDIA ALKEM LABORATORIES/
SANOFI INDIA
 
P/E (TTM) x - 32.8 - View Chart
P/BV x 7.6 6.3 121.2% View Chart
Dividend Yield % 0.6 1.4 39.6%  

Financials

 ALKEM LABORATORIES   SANOFI INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SANOFI INDIA
Dec-16
ALKEM LABORATORIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,5894,560 34.8%   
Low Rs1,2324,400 28.0%   
Sales per share (Unadj.) Rs417.51,028.5 40.6%  
Earnings per share (Unadj.) Rs56.3129.0 43.7%  
Cash flow per share (Unadj.) Rs64.7186.0 34.8%  
Dividends per share (Unadj.) Rs12.7068.00 18.7%  
Dividend yield (eoy) %0.91.5 59.3%  
Book value per share (Unadj.) Rs292.9753.6 38.9%  
Shares outstanding (eoy) m119.5723.03 519.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 77.6%   
Avg P/E ratio x25.134.7 72.1%  
P/CF ratio (eoy) x21.824.1 90.5%  
Price / Book Value ratio x4.85.9 81.0%  
Dividend payout %22.652.7 42.8%   
Avg Mkt Cap Rs m168,653103,174 163.5%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m9,1713,592 255.3%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m49,91523,686 210.7%  
Other income Rs m1,645708 232.4%   
Total revenues Rs m51,56124,394 211.4%   
Gross profit Rs m8,4825,281 160.6%  
Depreciation Rs m1,0061,313 76.6%   
Interest Rs m67115 4,470.7%   
Profit before tax Rs m8,4514,661 181.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,691 95.0%   
Profit after tax Rs m6,7312,970 226.6%  
Gross profit margin %17.022.3 76.2%  
Effective tax rate %19.036.3 52.4%   
Net profit margin %13.512.5 107.5%  
BALANCE SHEET DATA
Current assets Rs m27,06215,673 172.7%   
Current liabilities Rs m15,3246,678 229.5%   
Net working cap to sales %23.538.0 61.9%  
Current ratio x1.82.3 75.2%  
Inventory Days Days6776 87.5%  
Debtors Days Days4122 185.0%  
Net fixed assets Rs m12,6108,098 155.7%   
Share capital Rs m239230 103.8%   
"Free" reserves Rs m34,49017,088 201.8%   
Net worth Rs m35,02717,356 201.8%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38725,400 214.1%  
Interest coverage x13.6311.7 4.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 98.4%   
Return on assets %13.611.8 115.8%  
Return on equity %19.217.1 112.3%  
Return on capital %24.926.9 92.3%  
Exports to sales %12.924.5 52.9%   
Imports to sales %3.128.0 11.0%   
Exports (fob) Rs m6,4615,801 111.4%   
Imports (cif) Rs m1,5406,627 23.2%   
Fx inflow Rs m6,5637,145 91.9%   
Fx outflow Rs m3,0126,846 44.0%   
Net fx Rs m3,552299 1,187.8%   
CASH FLOW
From Operations Rs m7,2593,226 225.0%  
From Investments Rs m1,864-1,555 -119.9%  
From Financial Activity Rs m-9,273-1,818 510.0%  
Net Cashflow Rs m-150-147 102.0%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 33.1 14.4 229.9%  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 15,184 450.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - J.B.CHEMICALS COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS